公开(公告)号：US20170266134A1

公开(公告)日：2017-09-21

申请号：US15310351

申请日：2015-05-12

Applicant: SUNOVION PHARMACEUTICALS INC.

Inventor： Antony D. LOEBEL ,  Kenneth S. KOBLAN

IPC: A61K31/135 ,  A61K9/00

CPC classification number: A61K31/135 ,  A61K9/0053 ,  A61K9/4858

Abstract: Dosage forms and treatment regimens employing dasotraline for treating Attention Deficit Hyperactivity Disorder (ADHD) are disclosed. The compositions described herein exhibit no abuse potential.

公开(公告)号：US20230241024A1

公开(公告)日：2023-08-03

申请号：US17933881

申请日：2022-09-21

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： Linda Jane BRISTOW ,  Nina DEDIC ,  Eva HAJOS-KORCSOK ,  Seth Cabot HOPKINS ,  Philip Glyn JONES ,  Kenneth S. KOBLAN ,  Snezana MILANOVIC ,  Colleen Marie SYNAN ,  Kuangnan XIONG

IPC: A61K31/381 ,  A61P3/04 ,  A61P3/10 ,  A61P25/18 ,  A61K31/5513

CPC classification number: A61K31/381 ,  A61K31/5513 ,  A61P3/04 ,  A61P3/10 ,  A61P25/18

Abstract: Provided herein are compounds, pharmaceutical compositions, and methods of use thereof, including methods of treating metabolic disorders and psychiatric disorders and diseases associated with metabolic disorders. For example, provided herein is Compound 1:





or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions and methods of use thereof, including methods of treating metabolic disorders and psychiatric disorders associated with metabolic disorders.

公开(公告)号：US20170266133A1

公开(公告)日：2017-09-21

申请号：US15310344

申请日：2015-05-12

Applicant: SUNOVION PHARMACEUTICALS INC.

Inventor： Antony D. LOEBEL ,  Kenneth S. KOBLAN

IPC: A61K31/135 ,  A61K9/00

CPC classification number: A61K31/135 ,  A61K9/0053 ,  A61K9/4858 ,  A61K31/136

Abstract: Dosage forms and treatment regimens employing dasotraline for treating Attention Deficit Hyperactivity Disorder (ADHD) are disclosed. The compositions described herein exhibit no abuse potential.